{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:09:37Z","timestamp":1792638577082,"version":"4.5.0"},"reference-count":34,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Osimertinib is the preferred treatment for patients with\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      -mutated advanced non-small cell lung cancer (NSCLC) in several settings; however, disease progression is common, and treatment options after progression are limited. Datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate comprising a humanized anti-trophoblast cell-surface antigen 2 (TROP 2) monoclonal antibody conjugated to a potent topoisomerase I inhibitor via a plasma-stable linker, has demonstrated efficacy in advanced NSCLC, including previously treated\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      -mutated advanced NSCLC. Combining osimertinib and Dato-DXd may overcome heterogeneous osimertinib resistance mechanisms and limit tumor progression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>\n                      TROPION-Lung15 is an ongoing, phase III, open-label, sponsor-blind, multicenter, randomized trial evaluating Dato-DXd\u2009\u00b1\u2009osimertinib versus chemotherapy in patients with\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      -mutated advanced NSCLC and disease progression on prior osimertinib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and design:<\/jats:title>\n                    <jats:p>Approximately 630 patients with histologically\/cytologically confirmed non-squamous NSCLC, documented epidermal growth factor receptor tyrosine kinase inhibitor-sensitive mutations, and radiologic progression on prior osimertinib monotherapy will be enrolled. Patients will be randomized 1:1:1 to Dato-DXd (6\u2009mg\/kg intravenously every 3\u2009weeks), osimertinib (80\u2009mg orally once daily) plus Dato-DXd, or platinum-doublet chemotherapy, stratified by the history\/presence of brain metastases (yes vs no), prior osimertinib therapy (adjuvant vs post-chemoradiotherapy\/first-line vs second-line), and race. Treatment will continue until radiological progression (per Response Evaluation Criteria in Solid Tumors version 1.1), unacceptable toxicity, or another discontinuation criterion is met. The dual primary endpoints are progression-free survival (PFS) by blinded independent central review (BICR) for osimertinib\u2009+\u2009Dato-DXd and PFS by BICR for Dato-DXd alone versus chemotherapy. Secondary endpoints include overall survival, central nervous system PFS by BICR, and safety\/tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics:<\/jats:title>\n                    <jats:p>The study is approved by independent ethics committees\/institutional review boards at each center. Patients will provide written informed consent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>\n                      TROPION-Lung15 will assess Dato-DXd\u2009\u00b1\u2009osimertinib in patients with\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      -mutated advanced NSCLC and disease progression on prior osimertinib. Data from this study could lead to a new treatment option in this setting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov identifier: NCT06417814 (date of registration: May 13, 2024).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359251385410","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T10:40:16Z","timestamp":1766486416000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with\n                    <i>EGFR<\/i>\n                    -mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib"],"prefix":"10.1177","volume":"17","author":[{"given":"Daniel Shao-Weng","family":"Tan","sequence":"first","affiliation":[{"name":"Medical Oncology Department, National Cancer Centre Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Catalan Institute of Oncology, IDIBELL, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parneet","family":"Cheema","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, William Osler Health Sciences, Brampton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[{"name":"Guangdong Provincial People\u2019s Hospital, Lung Cancer Institute, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[{"name":"Hematology\u2013Oncology Department, Samsung Medical Center, Seoul, Republic of South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Tanizaki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Grainger","sequence":"additional","affiliation":[{"name":"Biostatistics, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Nizialek","sequence":"additional","affiliation":[{"name":"Oncology R&amp;D, AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Forcina","sequence":"additional","affiliation":[{"name":"Oncology R&amp;D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toon","family":"van der Gronde","sequence":"additional","affiliation":[{"name":"Oncology R&amp;D, AstraZeneca, New York, NY, USA"},{"name":"Clinical Science, Daiichi Sankyo, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0377-9510","authenticated-orcid":false,"given":"Helena A.","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medicine (Medical Oncology), Memorial Sloan-Kettering Cancer Center, 530 East 74th Street, New York, NY 10021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0337"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.3118"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.9363"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027071"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304594"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02219"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.013"},{"key":"e_1_3_4_14_2","unstructured":"Hendriks L Cortiula F Mariaidze E et al. ESMO oncogene-addicted metastatic non-small-cell lung cancer living guideline v1.2 (Original publication: Clinical Practice Guideline citation. Ann Oncol 2023; 34(4): 339\u2013333) https:\/\/www.esmo.org\/living-guidelines\/esmo-oncogene-addicted-non-small-cell-lung-cancer-living-guideline (2025 accessed August 29 2025)."},{"key":"e_1_3_4_15_2","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, Version 2024.3","volume":"42","author":"Owen DH","year":"2025","unstructured":"Owen DH, Ismaila N, Ahluwalia A, et al. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, Version 2024.3. J Clin Oncol 2025; 42: e44\u2013e59.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1994"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00051"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01324"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02186"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030841"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.003"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210225"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.07.007"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.117"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0206"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01679-1"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01544"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01349"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.06.002"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-LB458"},{"key":"e_1_3_4_31_2","volume-title":"Osimertinib\u2009+\u2009datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC whose disease progressed on first-line osimertinib: ORCHARD","author":"Le X","unstructured":"Le X, Hendriks L, Morabito A, et al. Osimertinib\u2009+\u2009datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC whose disease progressed on first-line osimertinib: ORCHARD. Oral presentation 10 at the European Lung Cancer Congress (ELCC), 26\u221229 March 2025, Paris, France."},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081477"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00059"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.118"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad052"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251385410","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251385410","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251385410","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:33:31Z","timestamp":1777588411000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251385410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":34,"alternative-id":["10.1177\/17588359251385410"],"URL":"https:\/\/doi.org\/10.1177\/17588359251385410","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"article-number":"17588359251385410"}}